Targeted therapies in bone sarcomas: Current approach and future directions

Jessica Lee Yarber, Mark Agulnik

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


Introduction: Bone sarcomas are rare malignancies and once advanced, there is limited response to current chemotherapeutic regimens. Targeted therapies could have substantial impact on these diseases. Areas covered: Specific molecular targets of bone sarcomas are reviewed along with the various targeted therapies that have potential to change the outcome of these chemotherapy resistant diseases. Expert opinion: There are promising pathways identified that targeted inhibitors could provide better treatment options for metastatic bone sarcomas. There is a strong need for continued Phase II and III clinical trials investigating these molecularly targeted therapies.

Original languageEnglish (US)
Pages (from-to)973-979
Number of pages7
JournalExpert Opinion on Investigational Drugs
Issue number7
StatePublished - Jul 2011


  • bone sarcoma
  • molecular targets
  • review
  • targeted therapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Targeted therapies in bone sarcomas: Current approach and future directions'. Together they form a unique fingerprint.

Cite this